p-chlorophenyl chloramine | 57311-92-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-chlorophenyl chloramine
• 英文别名: N-chloro-4-chloroaniline；N,4-Dichloroaniline
• CAS: 57311-92-9
• 化学式: C₆H₅Cl₂N
• 分子量: 162.018
• InChiKey: DGUDMXWYKSHBBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  p-chlorophenyl chloramine 在 氨 作用下， 以 水 为溶剂， 以132.6 g的产率得到4-氯苯肼
  参考文献：
  名称：

  一种对氯苯肼的合成方法

  摘要：

  本发明公开了一种对氯苯肼的合成方法，其技术方案是先用次氯酸钠与对氯苯胺反应制取对氯苯基一氯胺，再将对氯苯基一氯胺与氨反应得到对氯苯肼。与传统的重氮化反应工艺制取对氯苯肼相比，本发明反应条件温和，对设备要求不高，反应步骤少，合成方法简单，副产物及废水量少，能耗低，收率高，生产成本低，是一种节能环保型新工艺。

  公开号：

  CN106866457A
• 作为产物：
  描述：

  对氯苯胺 在 sodium hypochlorite 作用下， 以 水 为溶剂， 生成 p-chlorophenyl chloramine
  参考文献：
  名称：

  一种对氯苯肼的合成方法

  摘要：

  本发明公开了一种对氯苯肼的合成方法，其技术方案是先用次氯酸钠与对氯苯胺反应制取对氯苯基一氯胺，再将对氯苯基一氯胺与氨反应得到对氯苯肼。与传统的重氮化反应工艺制取对氯苯肼相比，本发明反应条件温和，对设备要求不高，反应步骤少，合成方法简单，副产物及废水量少，能耗低，收率高，生产成本低，是一种节能环保型新工艺。

  公开号：

  CN106866457A

文献信息

• Synthesis of indoles from anilines and intermediates therein
  申请人：The Ohio State University Research Foundation

  公开号：US03992392A1

  公开（公告）日：1976-11-16

  Preparing indoles and intermediates therefor by reacting an N-haloaniline with a .beta.-carbonylic hydrocarbon sulfide to form an azasulfonium halide, reacting the azasulfonium halide with a strong base to form a thio-ether indole derivative, and then reducing the thio-ether indole, e.g. with Raney nickel, to form the indole compound. When an acetal or ketal of the .beta.-carbonyl hydrocarbon sulfide is used, the azasulfonium salt is treated with a base, and then with an acid to form the thio-ether indole derivative. When an .alpha.-ethyl-.beta. -carbonylic hydrocarbon sulfide is used, the resulting azosulfonium salt reacts with strong base to form a thio-ether indolenine derivative, which on reduction with Raney nickel or complex metal hydrides yields 3-substituted indoles. The aniline may be an aminopyridine to form an aza-indole compound in the process. The azasulfonium salts and thio-ether indole or thio-ether indolenine derivatives can be isolated and recovered from their respective reaction mixtures. The thio-ether-indole and thio-ether indolenine derivatives are useful as intermediates to make the indoles without the thio-ether group. The indoles are known compounds having a wide variety of uses, e.g., in making perfumes, dyes, amino acids, pharmaceuticals, agricultural chemicals and the like.

  通过将N-卤苯胺与β-羰基碳氢砜反应以形成氮硫杂环卤化物，然后将氮硫杂环卤化物与强碱反应以形成硫醚吲哚衍生物，然后还原硫醚吲哚，例如使用雷内镍，以形成吲哚化合物。当使用β-羰基碳氢砜的缩醛或缩酮时，处理氮硫杂环盐与碱，然后与酸反应以形成硫醚吲哚衍生物。当使用α-乙基-β-羰基碳氢砜时，生成的氮硫杂环盐与强碱反应以形成硫醚吲哚啉衍生物，然后通过雷内镍或复杂金属氢化物还原，得到3-取代吲哚。苯胺可以是氨基吡啶，以在过程中形成氮杂吲哚化合物。氮硫杂环盐和硫醚吲哚或硫醚吲哚啉衍生物可以从各自的反应混合物中分离和回收。硫醚吲哚和硫醚吲哚啉衍生物可用作制备不含硫醚基团的吲哚的中间体。吲哚是已知化合物，具有各种用途，例如制造香水、染料、氨基酸、药品、农药等。
• BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY
  申请人：Whiteford Jeffery A.

  公开号：US20100004218A1

  公开（公告）日：2010-01-07

  A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to control fluid and/or waste levels.

  描述了一种药用活性剂、一种药用活性剂载体及其使用方法。在一些实施例中，系统可能包括一种组合物。该组合物可能包括一个或多个桥联多环化合物。至少一个桥联多环化合物可能包括至少两个环状基团，并且至少两种药用活性剂可能与桥联多环化合物相关联。在一些实施例中，一个或多个桥联多环化合物可以被用于控制主体的液体和/或废物水平。
• BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS
  申请人：Whiteford Jeffery A.

  公开号：US20100016270A1

  公开（公告）日：2010-01-21

  A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to improve cardiac and/or cardiovascular health. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to control cholesterol levels.

  本文描述了一种药理活性剂、药理活性剂载体及其使用方法。在某些实施例中，该系统可能包括一种组合物。该组合物可能包括一个或多个桥接多环化合物。其中至少一个桥接多环化合物可能包括至少两个环状基团，并且至少有两种药理活性剂可能与桥接多环化合物相关联。在某些实施例中，可以向受试者施用一个或多个桥接多环化合物以改善心脏和/或心血管健康。在某些实施例中，可以向受试者施用一个或多个桥接多环化合物以控制胆固醇水平。
• AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS
  申请人：Boechat Nubia

  公开号：US20090054501A1

  公开（公告）日：2009-02-26

  This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII. where: X is an atom of “C” or “N;” where X is “N” the radicals do triazole ring are represented by: R 1 =COR 2 , CSR 3 , CN(R 4 )R 5 or CF 2 R 6 ; R 2 =H, NHNH 2 , alkyl, aryl substituted or not, OH, NR 7 R 8 or OR 9 ; R 3 =alkyl or aryl substituted or not; R 4 =H, OH, alkyl or aryl substituted or not; R 5 =R 6 =R 7 =R 8 =R 9 =R 10 =H, alkyl or aryl substituted or not; where X is “C” the radicals do imidazolic ring are represented by: R 1 =COR 2 ; R 2 =NHNH 2 , OH, OR 3 , or NR 4 R 5 ; R 3 =alkyl or aryl substituted or not; =R 5 H, alkyl or aryl substituted or not; R 10 =NHR 6 or NR 6 R 7 ; R 6 =R 7 =COR 8 ; R 8 =aryl substituted or not; while radical R n can be located in any one or in more than one of the carbon atoms of the aromatic ring, and these radicals can be equal or different, represented by hydrogen, alkylic groups with 1 or more carbon atoms in a linear or branched chain alkenes or alkynes, hydroxyl, hydroxyalkyl or oxygenated functions in acyclic or cyclic systems forming an heterocyclic ring, free or substituted amines, thioalkyl, donators and/or removing groupings of electrons or halogens, thus “n” can vary from 1 to 5. This invention also refers to a pharmaceutical composition comprising, as active principle, at least one of the azole compounds represented by the general formula VIII, to the use of such compositions and to method of treatment or inhibition de tuberculosis and leishmaniasis.

  本发明涉及新的1,2,3-三唑和咪唑化合物，这些化合物属于由通式VIII表示的化合物家族，其中：X是“C”或“N”的原子；当X为“N”时，三唑环的基团表示为：R1=COR2、CSR3、CN（R4）R5或CF2R6；R2=H、NHNH2、烷基、芳基取代或不取代、OH、NR7R8或OR9；R3=烷基或芳基取代或不取代；R4=H、OH、烷基或芳基取代或不取代；R5=R6=R7=R8=R9=R10=H、烷基或芳基取代或不取代；当X为“C”时，咪唑环的基团表示为：R1=COR2；R2=NHNH2、OH、OR3或NR4R5；R3=烷基或芳基取代或不取代；=R5H、烷基或芳基取代或不取代；R10=NHR6或NR6R7；R6=R7=COR8；R8=芳基取代或不取代；而基团Rn可以位于任何一个或多个芳香环的碳原子上，这些基团可以相等或不同，由氢、线性或支链烷基链上具有1个或多个碳原子的烷基基团、烯烃或炔烃、羟基、羟基烷基或在无环或环形系统中含氧杂环的功能、自由或取代的胺、硫代烷基、电子给体和/或电子受体基团或卤素表示，因此“n”可以从1到5变化。本发明还涉及一种制药组合物，其包含至少一种由通式VIII表示的唑类化合物作为活性成分，以及使用这种组合物的方法和治疗或抑制结核病和利什曼病的方法。
• Method for producing of polyarylene sulfides
  申请人：IDEMITSU PETROCHEMICAL CO. LTD.

  公开号：EP0215312A1

  公开（公告）日：1987-03-25

  Disclosed is a method for producing a polyarylene sulfide comprising contacting a dihalogenated aromatic compound with an alkali metal sulfide in a polar solvent, wherein a halogenated aromatic compound containing active hydrogen is present in the reaction system.

  本发明公开了一种生产聚芳基硫醚的方法，该方法包括在极性溶剂中将二卤代芳香族化合物与碱金属硫化物接触，其中反应体系中存在含有活性氢的卤代芳香族化合物。